Literature DB >> 10098737

Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts.

H B Ris1, T Krueger, A Giger, C K Lim, J C Stewart, U Althaus, H J Altermatt.   

Abstract

The photosensitizing properties of m-tetrahydroxyphenylchlorin (mTHPC) and polyethylene glycol-derivatized mTHPC (pegylated mTHPC) were compared in nude mice bearing human malignant mesothelioma, squamous cell carcinoma and adenocarcinoma xenografts. Laser light (20 J/cm2) at 652 nm was delivered to the tumour (surface irradiance) and to an equal-sized area of the hind leg of the animals after i.p. administration of 0.1 mg/kg body weight mTHPC and an equimolar dose of pegylated mTHPC, respectively. The extent of tumour necrosis and normal tissue injury was assessed by histology. Both mTHPC and pegylated mTHPC catalyse photosensitized necrosis in mesothelioma xenografts at drug-light intervals of 1-4 days. The onset of action of pegylated mTHPC seemed slower but significantly exceeds that of mTHPC by days 3 and 4 with the greatest difference being noted at day 4. Pegylated mTHPC also induced significantly larger photonecrosis than mTHPC in squamous cell xenografts but not in adenocarcinoma at day 4, where mTHPC showed greatest activity. The degree of necrosis induced by pegylated mTHPC was the same for all three xenografts. mTHPC led to necrosis of skin and underlying muscle at a drug-light interval of 1 day but minor histological changes only at drug-light intervals from 2-4 days. In contrast, pegylated mTHPC did not result in histologically detectable changes in normal tissues under the same treatment conditions at any drug-light interval assessed. In this study, pegylated mTHPC had advantages as a photosensitizer compared to mTHPC. Tissue concentrations of mTHPC and pegylated mTHPC were measured by high-performance liquid chromatography in non-irradiated animals 4 days after administration. There was no significant difference in tumour uptake between the two sensitizers in mesothelioma, adenocarcinoma and squamous cell carcinoma xenografts. Tissue concentration measurements were of limited use for predicting photosensitization in this model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098737      PMCID: PMC2362256          DOI: 10.1038/sj.bjc.6690170

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Toxicity of photodynamic therapy with photofrin in the normal rat brain.

Authors:  Y Ji; S K Powers; J T Brown; D Walstad; L Maliner
Journal:  Lasers Surg Med       Date:  1994       Impact factor: 4.025

2.  Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers.

Authors:  L Ma; J Moan; K Berg
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

3.  Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.

Authors:  F R Reale; T W Griffin; J M Compton; S Graham; P L Townes; A Bogden
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

4.  Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma.

Authors:  H B Ris; H J Altermatt; B Nachbur; J C Stewart; Q Wang; C K Lim; R Bonnett; U Althaus
Journal:  Int J Cancer       Date:  1993-01-02       Impact factor: 7.396

5.  Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index.

Authors:  H B Ris; H J Altermatt; C M Stewart; T Schaffner; Q Wang; C K Lim; R Bonnett; U Althaus
Journal:  Int J Cancer       Date:  1993-09-09       Impact factor: 7.396

6.  Heavy water delays growth of human carcinoma in nude mice.

Authors:  H J Altermatt; J O Gebbers; J A Laissue
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

7.  PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours.

Authors:  E Allémann; N Brasseur; O Benrezzak; J Rousseau; S V Kudrevich; R W Boyle; J C Leroux; R Gurny; J E Van Lier
Journal:  J Pharm Pharmacol       Date:  1995-05       Impact factor: 3.765

8.  Functional and histological bladder damage in mice after photodynamic therapy: the influence of sensitiser dose and time of administration.

Authors:  F A Stewart; Y Oussoren
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

9.  In vivo biological activity of the components of haematoporphyrin derivative.

Authors:  M C Berenbaum; R Bonnett; P A Scourides
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

10.  Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results.

Authors:  H B Ris; H J Altermatt; R Inderbitzi; R Hess; B Nachbur; J C Stewart; Q Wang; C K Lim; R Bonnett; M C Berenbaum
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

View more
  1 in total

1.  Bioconjugatable, PEGylated Hydroporphyrins for Photochemistry and Photomedicine. Narrow-Band, Red-Emitting Chlorins.

Authors:  Mengran Liu; Chih-Yuan Chen; Amit Kumar Mandal; Vanampally Chandrashaker; Rosemary B Evans-Storms; J Bruce Pitner; David F Bocian; Dewey Holten; Jonathan S Lindsey
Journal:  New J Chem       Date:  2016-07-21       Impact factor: 3.591

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.